VANDA PHARMACEUTICALS INC. Current Liabilities
VANDA PHARMACEUTICALS INC. (VNDA) had Current Liabilities of $164.03 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Liabilities, Current $164.03M.
- 2026-03-31: Liabilities, Current $135.58M.
- 2025-12-31: Liabilities, Current $145.16M.
- 2025-09-30: Liabilities, Current $117.87M.
| Period end | Liabilities, Current |
|---|---|
| 2026-06-30 | $164.03M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $135.58M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $145.16M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $117.87M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $121.49M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $103.92M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $99.98M 10-K · filed 2026-02-12 |
| 2024-09-30 | $89.09M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $93.79M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $93.34M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $87.70M 10-K · filed 2025-02-14 |
| 2023-09-30 | $84.84M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $87.40M 10-Q · filed 2023-07-28 |
| 2023-03-31 | $93.79M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $91.44M 10-K · filed 2024-02-08 |
| 2022-09-30 | $92.62M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $88.40M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $90.74M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $74.42M 10-K · filed 2023-02-09 |
| 2021-09-30 | $72.00M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $71.99M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $61.78M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $65.94M 10-K · filed 2022-02-24 |
| 2020-09-30 | $61.36M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $61.59M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $59.22M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $59.51M 10-K · filed 2021-02-11 |
| 2019-09-30 | $60.00M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $62.58M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $59.27M 10-Q · filed 2019-05-03 |
| 2018-12-31 | $53.02M 10-K · filed 2020-02-26 |
| 2018-09-30 | $46.24M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $46.88M 10-Q · filed 2018-08-02 |
| 2018-03-31 | $71.95M 10-Q · filed 2018-05-02 |
| 2017-12-31 | $70.36M 10-K · filed 2019-02-19 |
| 2017-09-30 | $71.54M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $75.44M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $72.97M 10-Q · filed 2017-05-03 |
| 2016-12-31 | $50.32M 10-K · filed 2018-02-15 |
| 2016-09-30 | $50.68M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $51.76M 10-Q · filed 2016-07-28 |
| 2016-03-31 | $55.04M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $51.32M 10-K · filed 2017-02-17 |
| 2015-09-30 | $45.89M 10-Q · filed 2015-11-04 |
| 2015-06-30 | $45.19M 10-Q · filed 2015-07-31 |
| 2015-03-31 | $31.79M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $7.79M 10-K · filed 2016-02-12 |
| 2014-09-30 | $38.84M 10-Q · filed 2014-10-27 |
| 2014-06-30 | $38.29M 10-Q · filed 2014-08-08 |
| 2014-03-31 | $45.40M 10-Q · filed 2014-05-08 |
| 2013-12-31 | $32.85M 10-K · filed 2015-03-13 |
| 2013-09-30 | $31.91M 10-Q · filed 2013-11-08 |
| 2013-06-30 | $31.93M 10-Q · filed 2013-07-31 |
| 2013-03-31 | $31.97M 10-Q · filed 2013-05-10 |
| 2012-12-31 | $32.26M 10-K · filed 2014-02-25 |
| 2012-09-30 | $34.63M 10-Q · filed 2012-11-08 |
| 2012-06-30 | $34.39M 10-Q · filed 2012-08-03 |
| 2012-03-31 | $32.66M 10-Q · filed 2012-05-09 |
| 2011-12-31 | $31.62M 10-K · filed 2013-02-26 |
| 2011-09-30 | $33.64M 10-Q · filed 2011-11-07 |
| 2011-06-30 | $32.86M 10-Q · filed 2011-08-05 |
| 2010-12-31 | $31.03M 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |